|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 13/10 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K 39/04 | (2006.01) |
| (11) | Number of the document | 3291831 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16724315.3 |
| Date of filing the European patent application | 2016-05-03 | |
| (97) | Date of publication of the European application | 2018-03-14 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-30 |
| (46) | Date of publication of the claims translation | 2021-02-25 |
| (86) | Number | PCT/EP2016/059872 |
| Date | 2016-05-03 |
| (87) | Number | WO 2016/177717 |
| Date | 2016-11-10 |
| (30) | Number | Date | Country code |
| 15166206 | 2015-05-04 | EP | |
| 201562387407 P | 2015-12-23 | US |
| (72) |
GRODE, Leander, DE
|
| (73) |
Vakzine Projekt Management GmbH,
Mellendorfer Strasse 9, 30625 Hannover,
DE
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Rekombinantinė bakterija kaip imunoterapinis agentas, skirtas vėžio gydymui |
| RECOMBINANT MYCOBACTERIUM AS AN IMMUNOTHERAPEUTIC AGENT FOR THE TREATMENT OF CANCER |
| Payment date | Validity (years) | Amount | |
| 2025-04-24 | 10 | 231.00 EUR |
| 2026-05-03 |